science
CREATE Medicines Raises $122 Million to Advance CAR-T Candidates Into Human Trials
The biotechnology company, formerly known as Myeloid Therapeutics, secured the funding from Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. CREATE Medicines, cofounded by Siddhartha Mukherjee, is developing CAR-T therapies using myeloid cells to target solid tumors and has expanded into autoimmune disease research.
May 14, 7:00 AM·1m read1 source
rte.ieAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
CREATE Medicines has raised $122 million to propel the company’s first CAR-T candidates through human trials, the biotech told STAT exclusively. The funding round included Newpath Partners, ARCH Venture Partners and Hatteras Venture Partners. CREATE Medicines is developing CAR-T therapies using a type of immune agent called myeloid cells.
Up until last year, CREATE Medicines was known as Myeloid Therapeutics. The startup was cofounded by noted writer and oncologist Siddhartha Mukherjee to develop better CAR-T therapies, ideally to better attack solid tumors. The company rebranded last fall.
It expanded into autoimmune disease research, following a path taken by many other oncology CAR-T companies. CREATE Medicines plans to advance its first CAR-T candidates through human trials with the new capital. Executives express confidence they will win the “foot race” in a competitive field, according to the STAT report published May 14, 2026.
The article was written by Allison DeAngelis. Stat reported that the $122 million funding arrives as the company operates with a new name and an expanded pipeline. A 3-D illustration of CAR-T cell therapy in breast cancer accompanied the report.
Stat reported the details of the funding and the company’s strategic shifts in an exclusive story available to STAT+ subscribers.
